Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Biotech Pharmaceutical Co., Ltd..
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Biotech Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01074021
First received: February 21, 2010
Last updated: August 26, 2010
Last verified: September 2009

February 21, 2010
August 26, 2010
October 2009
June 2010   (final data collection date for primary outcome measure)
  • To determine the local-regional control rates of the disease in the advanced nasopharyngeal cancer patients subject to the treatment with Nimotuzumab in combination with chemoradiation [ Time Frame: 3 months after the Nimotuzumab treatment finished ] [ Designated as safety issue: No ]
  • To determine the safety of the treatment with Nimotuzumab in combination with chemoradiation [ Time Frame: within study period ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01074021 on ClinicalTrials.gov Archive Site
  • To determine the Disease-free survival、Tumor control probability、Distant recurrence rate in the patients subject to the treatment at years 1,2,3 [ Time Frame: 3 year ] [ Designated as safety issue: No ]
  • To determine the Progression free suivival、Diease free survival、Overall survival in the patients subject to the treatment [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer

Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate nimotuzumab in different indications. Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. The Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the clinical efficacy, and safety of the combination of Nimotuzumab administered concomitantly with chemotherapy and radiotherapy in patients with advanced nasopharyngeal cancer.

Patients with advanced nasopharyngeal cancer will be randomized to 2 arms. The patients in experimental arm will be treated with Nimotuzumab which will be used concurrently with radiotherapy and chemotherapy. The chemotherapy regimen were Cisplatin monotherapy. The active comparator arm will be administered chemotherapy and radiotherapy only. The dose and regimen were the same with experiment arm. The patients'hematopoietic , hepatic and renal function tests will be monitored weekly, a physical exam and reassessment of the tumor will be performed at the first and the fourth month, and followup every six months to evaluate the survival index in three years after the study.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Advanced Nasopharyngeal Cancer
  • Drug: Nimotuzumab

    Nimotuzumab:(200mg/w,weekly, 7-8 weeks, one week before radiotherapy)

    Radiotherapy:

    IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.

    CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin

    Chemotherapy:

    Cisplatin (100 mg/m2,1 time/21d, 3 times,on days 2, 23, 44 during the radiotherapy)

  • Drug: placebo plus chemoradiotherapy

    Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy

    Radiotherapy:

    IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.

    CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin

    Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times,on days 2, 23, 44 during the radiotherapy)

  • Experimental: Nimotuzumab plus chemoradiotherapy
    Intervention: Drug: Nimotuzumab
  • Placebo Comparator: placebo plus chemoradiotherapy
    Intervention: Drug: placebo plus chemoradiotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
480
June 2013
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Joined the study voluntary and signed informed consent form
  • Age 18-70,both genders.
  • Nasopharyngeal cancer was confirmed by pathology.
  • Nasopharyngeal cancer 2008 Stages: Ⅲ/Ⅳa.
  • Primary lesions can measurable.
  • Karnofsky Performance Scale >70.
  • Life expectancy of more than 6 months.
  • Use of an effective contraceptive method for women when there is a risk of pregnancy during the study.
  • Haemoglobin≥100g/L ,WBC ≥4×109/L, platelet count≥100×109/L
  • Hepatic function:ALAT、ASAT< 1.5 x ULN, TBIL< 1.5 x ULN
  • Renal function: Creatinine < 1.5 x ULN

Exclusion Criteria:

  • Evidence of distant metastasis
  • Primary lesions or lymph node have been operated (except of operation for biopsy)
  • Previous radiotherapy
  • Received other anti EGFR monoclonal antibody treatment
  • Previous chemotherapy or immunization therapy
  • Other malignant tumor (except of Non-melanoma Skin Cancer or carcinoma in situ of cervix)
  • Participation in other interventional clinical trials within 1 month
  • Peripheral neuropathy is more than I stage
  • Pregnant or breast-feeding women and women who refused to take contraceptive method
  • History of serious allergic or allergy
  • History of Serious lung or heart disease
  • Refused or can't signed informed consent form
  • Drug abuse or alcohol addiction
  • Personality or psychiatric disease, and persons without capacity for civil conduct or persons with limited capacity for civil conduct
Both
18 Years to 70 Years
No
Not Provided
China
 
NCT01074021
BT-CT-001
Yes
Jianji-Pan, Fujian Provincial Cancer Hospital
Biotech Pharmaceutical Co., Ltd.
Not Provided
Principal Investigator: Jianji Pan Fujian Cancer Hospital
Biotech Pharmaceutical Co., Ltd.
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP